Resources from the same session
Molecular diagnostics for detection of RET aberrations in non-small cell lung cancer: How, when and how often
Presenter: Frédérique Penault-Llorca
Session: ESMO Colloquium co-supported by Lilly Oncology & Thermo Fisher Scientific - Targeting RET in lung cancer: State of the art in testing and therapeutics
Resources:
Slides
Webcast
Targeting the RET fusion in patients with advanced non-small cell lung cancer: Efficacy, toxicity, quality of life and cost
Presenter: Oliver Gautschi
Session: ESMO Colloquium co-supported by Lilly Oncology & Thermo Fisher Scientific - Targeting RET in lung cancer: State of the art in testing and therapeutics
Resources:
Slides
Webcast
Two clinical cases of patients with NSCLC harbouring RET abnormalities: Critical analysis of management according to ESMO Guidelines for NSCLC and NGS use, MCBS, ESCAT
Presenter: Antonio Passaro
Session: ESMO Colloquium co-supported by Lilly Oncology & Thermo Fisher Scientific - Targeting RET in lung cancer: State of the art in testing and therapeutics
Resources:
Slides
Webcast
Live conclusions
Presenter: Federico Cappuzzo
Session: ESMO Colloquium co-supported by Lilly Oncology & Thermo Fisher Scientific - Targeting RET in lung cancer: State of the art in testing and therapeutics
Resources:
Webcast
Q&A and live discussion
Presenter: All Speakers
Session: ESMO Colloquium co-supported by Lilly Oncology & Thermo Fisher Scientific - Targeting RET in lung cancer: State of the art in testing and therapeutics
Resources:
Webcast